PMC:7200337 / 99901-100106
Annnotations
LitCovid-PD-UBERON
| Id | Subject | Object | Predicate | Lexical cue | uberon_id |
|---|---|---|---|---|---|
| T99 | 154-159 | Body_part | denotes | scale | http://purl.obolibrary.org/obo/UBERON_0002542 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 82-83 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T2 | 124-128 | http://purl.obolibrary.org/obo/UBERON_0000473 | denotes | test |
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 3328 | 193-195 | Gene | denotes | to | Gene:6999 |
| 3329 | 151-153 | Gene | denotes | to | Gene:6999 |
| 3330 | 112-114 | Gene | denotes | to | Gene:6999 |
| 3331 | 196-204 | Species | denotes | patients | Tax:9606 |
| 3336 | 9-20 | Species | denotes | recombinant | Tax:575864 |
| 3339 | 21-25 | Chemical | denotes | nAbs |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T586 | 0-205 | Sentence | denotes | Although recombinant nAbs could provide an effective treatment, they will require a significant time investment to develop, test, and bring production to scale before becoming widely available to patients. |